questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Globulines
Sérum-globulines
Immunoglobulines
Sous-unités des immunoglobulines
Chaines légères des immunoglobulines
Chaines légères kappa des immunoglobulines
Chaines légères kappa des immunoglobulines : Questions médicales fréquentes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chaines légères kappa des immunoglobulines : Questions médicales les plus fréquentes",
"headline": "Chaines légères kappa des immunoglobulines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chaines légères kappa des immunoglobulines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-29",
"dateModified": "2025-03-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chaines légères kappa des immunoglobulines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Chaines légères des immunoglobulines",
"url": "https://questionsmedicales.fr/mesh/D007147",
"about": {
"@type": "MedicalCondition",
"name": "Chaines légères des immunoglobulines",
"code": {
"@type": "MedicalCode",
"code": "D007147",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.705.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chaines légères kappa des immunoglobulines",
"alternateName": "Immunoglobulin kappa-Chains",
"code": {
"@type": "MedicalCode",
"code": "D007145",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Philipp Schwenkenbecher",
"url": "https://questionsmedicales.fr/author/Philipp%20Schwenkenbecher",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Hannover Medical School, 30625 Hannover, Germany."
}
},
{
"@type": "Person",
"name": "Stefan Gingele",
"url": "https://questionsmedicales.fr/author/Stefan%20Gingele",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Hannover Medical School, 30625 Hannover, Germany."
}
},
{
"@type": "Person",
"name": "Kurt-Wolfram Sühs",
"url": "https://questionsmedicales.fr/author/Kurt-Wolfram%20S%C3%BChs",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Hannover Medical School, 30625 Hannover, Germany."
}
},
{
"@type": "Person",
"name": "Thomas Skripuletz",
"url": "https://questionsmedicales.fr/author/Thomas%20Skripuletz",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Hannover Medical School, 30625 Hannover, Germany."
}
},
{
"@type": "Person",
"name": "Morie A Gertz",
"url": "https://questionsmedicales.fr/author/Morie%20A%20Gertz",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology, Mayo Clinic, Rochester, Minnesota."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study.",
"datePublished": "2022-11-14",
"url": "https://questionsmedicales.fr/article/36376096",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/NXI.0000000000200049"
}
},
{
"@type": "ScholarlyArticle",
"name": "An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35610346",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41375-022-01599-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis.",
"datePublished": "2023-10-25",
"url": "https://questionsmedicales.fr/article/37954589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1288169"
}
},
{
"@type": "ScholarlyArticle",
"name": "High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis.",
"datePublished": "2023-01-20",
"url": "https://questionsmedicales.fr/article/36742305",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1106028"
}
},
{
"@type": "ScholarlyArticle",
"name": "Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study.",
"datePublished": "2023-04-20",
"url": "https://questionsmedicales.fr/article/37086651",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ebiom.2023.104573"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Globulines",
"item": "https://questionsmedicales.fr/mesh/D005916"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sérum-globulines",
"item": "https://questionsmedicales.fr/mesh/D012712"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007136"
},
{
"@type": "ListItem",
"position": 7,
"name": "Sous-unités des immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D050440"
},
{
"@type": "ListItem",
"position": 8,
"name": "Chaines légères des immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007147"
},
{
"@type": "ListItem",
"position": 9,
"name": "Chaines légères kappa des immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007145"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chaines légères kappa des immunoglobulines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chaines légères kappa des immunoglobulines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chaines légères kappa des immunoglobulines",
"description": "Comment diagnostiquer une anomalie des chaînes kappa ?\nQuels tests sont utilisés pour évaluer les chaînes kappa ?\nQuels marqueurs indiquent une surproduction de chaînes kappa ?\nQuel rôle joue la biopsie dans le diagnostic ?\nLes tests génétiques sont-ils utiles pour les chaînes kappa ?",
"url": "https://questionsmedicales.fr/mesh/D007145?page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chaines légères kappa des immunoglobulines",
"description": "Quels symptômes sont associés à une dysrégulation des chaînes kappa ?\nComment les chaînes kappa affectent-elles le système immunitaire ?\nLes douleurs osseuses sont-elles liées aux chaînes kappa ?\nQuels signes cliniques peuvent indiquer une maladie des chaînes kappa ?\nLes symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D007145?page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chaines légères kappa des immunoglobulines",
"description": "Peut-on prévenir les maladies liées aux chaînes kappa ?\nLes habitudes de vie influencent-elles les chaînes kappa ?\nLe dépistage précoce est-il important ?\nLes vaccinations sont-elles recommandées ?\nComment le stress affecte-t-il les chaînes kappa ?",
"url": "https://questionsmedicales.fr/mesh/D007145?page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chaines légères kappa des immunoglobulines",
"description": "Quels traitements sont disponibles pour les anomalies des chaînes kappa ?\nLa transplantation de moelle osseuse est-elle une option ?\nLes médicaments immunomodulateurs sont-ils efficaces ?\nComment la thérapie ciblée aide-t-elle ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D007145?page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chaines légères kappa des immunoglobulines",
"description": "Quelles complications peuvent survenir avec des chaînes kappa anormales ?\nLes chaînes kappa peuvent-elles causer des cancers ?\nComment les chaînes kappa affectent-elles la santé osseuse ?\nLes troubles neurologiques sont-ils possibles ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D007145?page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chaines légères kappa des immunoglobulines",
"description": "Quels sont les principaux facteurs de risque pour les anomalies des chaînes kappa ?\nLe tabagisme influence-t-il les chaînes kappa ?\nLes infections virales sont-elles un facteur de risque ?\nL'exposition à des produits chimiques est-elle préoccupante ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D007145?page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des chaînes kappa ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dosage des immunoglobulines et une électrophorèse des protéines sériques sont effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les chaînes kappa ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la mesure des chaînes légères libres et l'analyse de la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Quels marqueurs indiquent une surproduction de chaînes kappa ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des chaînes légères kappa libres dans le sang peut indiquer une surproduction."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie de la moelle osseuse aide à évaluer la présence de plasmocytes anormaux."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour les chaînes kappa ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des anomalies génétiques associées à des maladies des plasmocytes."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une dysrégulation des chaînes kappa ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, infections fréquentes et douleurs osseuses."
}
},
{
"@type": "Question",
"name": "Comment les chaînes kappa affectent-elles le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une production anormale peut entraîner une immunodéficience et une susceptibilité accrue aux infections."
}
},
{
"@type": "Question",
"name": "Les douleurs osseuses sont-elles liées aux chaînes kappa ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent résulter de l'accumulation de cellules plasmatiques dans les os."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent indiquer une maladie des chaînes kappa ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'anémie, l'hypercalcémie et des lésions cutanées peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus prononcés chez les personnes âgées en raison de comorbidités."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux chaînes kappa ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles les chaînes kappa ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée et l'exercice peuvent soutenir le système immunitaire."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce est-il important ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un dépistage précoce peut aider à identifier les anomalies avant qu'elles ne s'aggravent."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent aider à prévenir les infections chez les patients à risque."
}
},
{
"@type": "Question",
"name": "Comment le stress affecte-t-il les chaînes kappa ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut affaiblir le système immunitaire, augmentant le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les anomalies des chaînes kappa ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et les thérapies ciblées."
}
},
{
"@type": "Question",
"name": "La transplantation de moelle osseuse est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être envisagée pour les cas avancés de maladies des chaînes kappa."
}
},
{
"@type": "Question",
"name": "Les médicaments immunomodulateurs sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent aider à réguler la réponse immunitaire et réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Comment la thérapie ciblée aide-t-elle ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle cible spécifiquement les cellules malignes, réduisant ainsi les effets secondaires."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des chaînes kappa anormales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance rénale, les infections et les troubles osseux."
}
},
{
"@type": "Question",
"name": "Les chaînes kappa peuvent-elles causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surproduction peut être associée à des cancers comme le myélome multiple."
}
},
{
"@type": "Question",
"name": "Comment les chaînes kappa affectent-elles la santé osseuse ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner une déminéralisation osseuse et des fractures fréquentes."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent inclure des troubles neurologiques en raison de l'inflammation."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les anomalies des chaînes kappa ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, des antécédents familiaux et certaines maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les chaînes kappa ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs maladies hématologiques."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le VIH, peuvent augmenter le risque d'anomalies des chaînes kappa."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques est-elle préoccupante ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques toxiques peut augmenter le risque de maladies des chaînes kappa."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hématologiques augmentent le risque d'anomalies des chaînes kappa."
}
}
]
}
]
}
Kappa free light chains (KFLC) seem to efficiently diagnose MS. However, extensive cohort studies are lacking to establish consensus cut-offs, notably to rule out non-MS autoimmune CNS disorders. Our ...
We conducted a retrospective multicenter study involving 13 French MS centers. Patients were included if they had a noninfectious and nontumoral CNS disorder, eligible data concerning CSF and serum KF...
One thousand six hundred twenty-one patients were analyzed (675 MS, 90 CIS, 297 OIND, and 559 NINDC). KFLC index and KFLC IF had similar performances in diagnosing MS from nonselected controls and OIN...
KFLC biomarkers are efficient tools to separate patients with MS from controls, even when compared with other patients with CNS autoimmune disorder. Given these results, we suggest using KFLC index or...
This study provides Class III evidence that KFLC index or IF can be used to differentiate patients with MS from nonselected controls and from patients with other autoimmune CNS disorders....
Immunoglobulin light chain (AL) amyloidosis is caused by a small, minimally proliferating B-cell/plasma-cell clone secreting a patient-unique, aggregation-prone, toxic light chain (LC). The pathogenic...
The immunoglobulin kappa free light chain (KFLC) index has been proposed as a potentially suitable alternative to oligoclonal IgG bands (OCGB) for diagnosing multiple sclerosis (MS), offering automati...
This prospective cohort study aimed to determine the best utilization of OCGB and KFLC index in patients with a clinically isolated syndrome (CIS) followed for at least two years. OCGB and KFLC were a...
The study included 371 patients, with 260 (70.1 %) being women, and a median age of 34.9 (27.8 - 43.9) years. Using a cut-off value of 6.1, the KFLC index demonstrated a sensitivity and specificity of...
Combining the KFLC index and OCGB can provide an easily reproducible and accurate method for diagnosing MS, with OCGB primarily reserved for patients with a KFLC index < 6.1....
Evolving evidence suggests that measurement of cerebrospinal fluid (CSF) kappa free light chain (KFLC) synthesis has high diagnostic sensitivity and specificity for multiple sclerosis (MS), but its pr...
In a monocentric longitudinal retrospecitve cohort study, KFLC-index ([CSF KFLC/serum KFLC]/[CSF albumin/serum albumin]) measured by latex-enhanced immunonephelometry was prospectively determined as p...
In patients with KFLC-index>100 (n=31), 11 subjects (35.5%) showed reduced SDMT scores by ≥8 points at follow-up (mean follow-up time 7.3 ± 2.6 years), compared with their baseline scores (p=0.01). Ba...
Intrathecal KFLC synthesis has become an attractive diagnostic tool for MS. We show for the first time that in a real-world setting of early RRMS, KFLC-index predicted cognitive decline. Whether this ...
Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL)...
Patients with early MS who had cerebrospinal fluid (CSF) and serum sampling at disease onset were followed for four years. At baseline, age, sex, disease duration, number of T2-hyperintense (T2L), and...
A total of 86 patients at a mean age of 33 ± 10 years and with a female predominance of 67% were included; 36 (42%) patients experienced a second clinical attack during follow-up. Cox regression analy...
κ-FLC index and sNfL Z score have an additive predictive value for early MS disease activity that is independent of known predictors....
This study was funded by a grant of the charitable foundation of the Austrian Multiple Sclerosis Society....
Free light chain (FLC) measurements are important in diagnosing monoclonal gammopathies. As FLC are heterogeneous, different reagents and instruments for measuring FLC concentrations may give divergin...
The two main FLC assays, N Latex FLC (Siemens) and Serum Freelite (The Binding Site), using four nephelometric or turbidimetric instrument platforms, were compared. Results from 27 EQA rounds distribu...
The kappa (κ) FLC measurements deviated significantly over time, but when only nephelometry was used, deviation from the mean was lower (median ranges: -5% to 13 %). The CV was significantly higher fo...
Imprecision in λFLC affects the κFLC/λFLC ratio. This may be important in clinical assessment of patients, especially differentiating between monoclonal and polyclonal gammopathies....
Typically, myeloma cells express a monoclonal immunoglobulin (Ig), either heavy or light chain. Here, we present a case of multiple myeloma with clonal dual expression of kappa and lambda light chain ...
Free light chain (FLC) assays and the ratio of κ/λ are recommended for diagnosis, prognosis and monitoring of plasma cell dyscrasias (PCD). Limited data exists on FLC clinical specificity in patients ...
We assessed the κ, λ, and κ/λ FLC ratio using the FreeLite assay and the Sebia FLC ELISA assay in 176 patients with clinical presentations of fatigue, anemia, polyclonal hypergammaglobulinemia, joint ...
For the κ/λ ratio, 68.7 % (121/176) of specimens on the FreeLite and 87.5 % (154/176) of specimens on the Sebia assay were within RI. For κ, 68.2 % (120/176) and 72.2 % (127/176) of results were outsi...
In a cohort of patients with signs and symptoms suggestive of PCDs, but ultimately diagnosed with other conditions, Sebia FLC had improved clinical specificity relative to FreeLite, if one was using a...
This study was done to evaluate the diagnostic accuracy of cerebrospinal fluid kappa free light chain (KFLC) for diagnosis of multiple sclerosis, against isoelectrofocusing (IEF) to detect oligoclonal...
Lymphoid aggregates are found in a minority of bone marrow biopsy and aspirate specimens, and when present, the distinction between benign and malignant aggregates can represent a diagnostic challenge...